Therapy Areas: Vaccines
South Africa's Biovac will commence production of Pfizer/ BioNTech COVID-19 vaccine in H2 2022
21 July 2021 -

The CEO of South African pharmaceutical company Biovac Institute has said that the company is aiming to start production of the Pfizer (NYSE:PFE)/ BioNTech (Nasdaq:BNTX) mRNA COVID-19 vaccine in the second half of next year, Reuters news agency reported on Wednesday.

Morena Makhoana told Reuters that Biovac would ramp up production of the COVID-19 vaccine before reaching output of 100 million doses a year around early 2023.